Emergent BioSolutions (EBS) Scheduled to Post Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS) will announce its earnings results after the market closes on Wednesday, May 1st. Analysts expect Emergent BioSolutions to post earnings of ($3.65) per share for the quarter. Emergent BioSolutions has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings data on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.44). Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. The company had revenue of $276.60 million during the quarter, compared to analyst estimates of $247.63 million. During the same quarter in the prior year, the company posted ($0.31) EPS. On average, analysts expect Emergent BioSolutions to post $-14 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Emergent BioSolutions Stock Performance

NYSE EBS traded down $0.04 on Tuesday, reaching $1.86. The stock had a trading volume of 221,861 shares, compared to its average volume of 2,560,583. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.54 and a current ratio of 1.04. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $10.88. The business has a 50 day moving average price of $2.45 and a 200 day moving average price of $2.23.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “buy” rating and issued a $5.00 price target on shares of Emergent BioSolutions in a research report on Thursday, April 11th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.